Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Secondary acute lymphoblastic leukemia more lethal than de novo

Publish date:: May 14, 2020

Key clinical point: Adult patients with secondary ALL had poorer overall survival than de novo ALL patients.

Major finding: Overall survival up to 5-years of the de novo ALL group was higher than that of the secondary ALL group at aged 18-75 years (P < .001).

Study details: Retrospective analysis of 7,454 cases of de novo ALL and 851 cases of secondary ALL from the SEER database.

Disclosures: The authors declared they had no conflicts of interest.

Citation:

Zhong J et al. Clin Lymphoma, Myeloma Leuk. 2020 Apr 30; doi.org/10.1016/j.clml.2020.04.013.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

Study: Complications from childhood ALL and its treatment are common, but can be managed,